Verschoor AJ, Bovee JVMG, Mastboom MJL, Sander Dijkstra PD, Van De Sande MAJ, Gelderblom H. Incidence and demographics of giant cell tumor of bone in The Netherlands: first nationwide Pathology Registry Study. Acta Orthop England. 2018;89:570–4.
CDM F, Bridge JA, MF HPCW, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC; 2013.
Branstetter DG, Nelson SD, Manivel JC, Blay J-Y, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res United States. 2012;18:4415–24.
McCarthy CL, Gibbons CLMH, Bradley KM, Hassan AB, Giele H, Athanasou NA. Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab. Clin Sarcoma Res England. 2017;7:19.
Kitazawa R, Haraguchi R, Fukushima M, Kitazawa S. Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion. Histochem Cell Biol Germany. 2018;149:405–15.
Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, et al. Adjuvant zoledronic acid in high-risk giant cell tumor of bone: a multicenter randomized phase II trial. Oncologist United States. 2019;24:889–e421.
Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer England. 2010;10:462.
Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int United States. 2004;75:71–7.
Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, et al. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World J Surg Oncol England. 2018;16:191.
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol England. 2010;11:275–80.
von Borstel D, Taguibao RA, Strle NA, Burns JE. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skelet Radiol Germany. 2017;46:571–8.
Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol Canada. 2013;20:e442–7.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res United States. 2011;469:591–9.
Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SPD, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol United States. 2015;22:2860–8.
Veng C, Jørgensen PH, Krog-Mikkelsen I, Stilling M. Measurement of bone mineral density as an efficacy marker in denosumab treatment of giant cell tumour of bone. BMJ Case Rep. 2017;2017:bcr2017220369.
Chawla S, Blay J-Y, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol England. 2019;20:1719–29.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am United States. 1987;69:106–14.
Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT-J France. 2017;3:54.
Takeuchi A, Tsuchiya H, Niu X, Ueda T, Jeon D-G, Wang EHM, et al. The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group. J Orthop Sci Japan. 2011;16:196–202.
Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GRJ. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics United States. 2013;33:197–211.
Hakozaki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K, et al. Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. Diagn Pathol England. 2014;9:111.
Matcuk GRJ, Patel DB, Schein AJ, White EA, Menendez LR. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skelet Radiol Germany. 2015;44:1027–31.
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res [Internet] England. 2016;6:15. Available from: http://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-016-0056-0.
Medellin MR, Fujiwara T, Tillman RM, Jeys LM, Gregory J, Stevenson JD, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J England. 2018;100-B:1626–32.
Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer England. 2016;59:1–12.
Osaka E, Okamura Y, Yoshida Y, Sugitani M, Tokuhashi Y. Intra-articular ectopic ossification associated with denosumab administration for giant cell tumor of bone with intra-articular pathological fracture. J Orthop Sci Japan. 2019;24:558–62.
Yi J, Lee YH, Kim SK, Kim SH, Song H-T, Shin K-H, et al. Response evaluation of giant-cell tumor of bone treated by denosumab: histogram and texture analysis of CT images. J Orthop Sci Japan. 2018;23:570–7.
Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol Off J Eur Soc Med Oncol England. 2015;26:2149–54.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer England. 2009;45:228–47.
Egbert RC, Folsom R, Bell J, Rajani R. Denosumab therapy for giant cell tumor of bone pulmonary metastasis. Case Rep Orthop. 2017;2017:2302597.
Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer England. 2017;76:118–24.
Yamagishi T, Kawashima H, Ogose A, Sasaki T, Hotta T, Inagawa S, et al. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: a case report. Oncol Lett Greece. 2016;11:243–6.
Oguro S, Okuda S, Sugiura H, Matsumoto S, Sasaki A, Susa M, et al. Giant cell tumors of the bone: changes in image features after denosumab administration. Magn Reson Med Sci Japan. 2018;17:325–30.
Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques. Radiology United States. 2012;265:340–56.
van der Heijden L, Dijkstra PDS, Blay J-Y, Gelderblom H. Giant cell tumour of bone in the denosumab era. Eur J Cancer England. 2017;77:75–83.
Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol Ireland. 2000;34:229–46.
van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology United States. 1998;208:821–8.
Satcher RL, Ravi V, Wang W-L, Oates S. Postpartum treatment of metastatic recurrent giant cell tumor of capitate bone of wrist. Am J Orthop (belle Mead NJ) United States. 2017;46:E269–75.
Ross AE, Bojescul JA, Kuklo TR. Giant cell tumor: a case report of recurrence during pregnancy. Spine (Phila Pa 1976) United States. 2005;30:E332–5.
Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol United States. 2013;42:27–40.
Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, et al. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochem Biophys Res Commun United States. 2017;491:614–21.
Boyce RW, Varela A, Chouinard L, Bussiere JL, Chellman GJ, Ominsky MS, et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone United States. 2014;64:314–25.
Zhang Y, Ilaslan H, Bauer TW. Giant cell tumor of bone: imaging and histology changes after denosumab treatment: Comment on: von Borstel D, Taguibao RA, Strle NA, Burns JE. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skelet Radiol Germany. 2017:961–2.
Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol England. 2016;69:240–7.
Akaike K, Suehara Y, Takagi T, Kaneko K, Saito T. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab. Skelet Radiol Germany. 2014;43:1767–72.
Park S-Y, Lee MH, Lee JS, Song JS, Chung HW. Ossified soft tissue recurrence of giant cell tumor of the bone: four case reports with follow-up radiographs, CT, ultrasound, and MR images. Skelet Radiol Germany. 2014;43:1457–63.
Cooper KL, Beabout JW, Dahlin DC. Giant cell tumor: ossification in soft-tissue implants. Radiology United States. 1984;153:597–602.
Ehara S, Nishida J, Abe M, Kawata Y, Saitoh H, Kattapuram SV. Ossified soft tissue recurrence of giant cell tumor of bone. Clin Imaging United States. 1992;16:168–71.
Teot LA, O’Keefe RJ, Rosier RN, O’Connell JX, Fox EJ, Hicks DG. Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation. Hum Pathol United States. 1996;27:625–32.
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer United States. 2003;97:2520–9.
Domovitov S V, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol. United States; 2010;17:694–701.
Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res United States. 2015;473:3050–5.
Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol England. 2017;47:1090–6.
Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat United States. 2019;18:1533033819840000.
Grote HJ, Braun M, Kalinski T, Pomjanski N, Back W, Bleyl U, et al. Spontaneous malignant transformation of conventional giant cell tumor. Skelet Radiol Germany. 2004;33:169–75.
Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol United States. 2016;40:72–80.
Wu C-C, Hsieh P-P. Denosumab-treated giant cell tumor of the bone mimicking low-grade central osteosarcoma. J Pathol Transl Med Korea (South). 2018;52:133–5.